Product Description: (Rac)-ZLc-002, an inhibitor of nNOS interaction with nitric oxide synthase 1 adaptor protein (NOS1AP), suppresses inflammatory nociception and chemotherapy-induced neuropathic pain and synergizes with Paclitaxel (HY-B0015) to reduce tumor cell viability[1][2].
Applications: COVID-19-immunoregulation
Formula: C10H17NO5
References: [1]Lee WH, Carey LM, Li LL, et al. ZLc002, a putative small-molecule inhibitor of nNOS interaction with NOS1AP, suppresses inflammatory nociception and chemotherapy-induced neuropathic pain and synergizes with paclitaxel to reduce tumor cell viability. Mol Pain. 2018;14:1744806918801224./[2]Zhu LJ, Shi HJ, Chang L, et al. nNOS-CAPON blockers produce anxiolytic effects by promoting synaptogenesis in chronic stress-induced animal models of anxiety. Br J Pharmacol. 2020;177(16):3674-3690.
Molecular Weight: 231.25
Compound Purity: 98.96
Research Area: Cancer; Inflammation/Immunology; Neurological Disease
Solubility: DMSO : 100 mg/mL (ultrasonic)
Target: NO Synthase
English
Deutsch
